Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-13
2005-12-13
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253120, C514S255010, C544S360000, C544S391000
Reexamination Certificate
active
06974817
ABSTRACT:
A compound of the formulaor the pharmaceutically acceptable salt thereof; wherein X, Y, a, b, c, d, R1, R2, R3and R5are as defined above useful to treat inflammation and other immune disorders.
REFERENCES:
patent: 3119742 (1964-01-01), Heimlich et al.
patent: 3492397 (1970-01-01), Peters et al.
patent: 3538214 (1970-11-01), Polli et al.
patent: 4060598 (1977-11-01), Groppenbacher et al.
patent: 4173626 (1979-11-01), Dempski et al.
patent: 2002/0107255 (2002-08-01), Blumberg et al.
patent: 2002/0119961 (2002-08-01), Blumberg et al.
patent: WO9856771 (1998-12-01), None
patent: WO0172728 (2001-10-01), None
Combadiere, Christophe, et. al., “Monocyte Chemoattractant Protein-3 is a Functional Ligand for CC Chemokine Receptors 1 and 2B,” The Journal of Biological Chemistry, vol. 270, No. 50, 1995, pp. 29671-29675.
Teran, Luis M., et. al., “Eosinophil Recruitment Following Allergen Challenge is Associated with the Release of the Chemokine RANTES into Asthmatic Airways,” The Journal of Immunology, 157, 1996, pp. 1806-1812.
Smith, Robert E., et. al., “Production and Function of Murine Macrophage Inflammatory Protein-1α in Bleomycin-Induced Lung Injury,” The Journal of Immunology, 153, 1994, pp. 4704-4712.
Cook, Donald N., et. al., “Requirement of MIP-1α for an Inflammatory Response to Viral Infection,” Science, vol. 269, 1995, pp. 583-585.
Maryanoff, Bruce E., et. al., “Stereochemistry of the Wittig Reaction. Effect of Nucleophilic Groups in the Phosphonium Ylide,” J. Am. Chem. Soc. 107, 1985, pp. 217-226.
Coligan, J.E., et. al., “Chapter 6: Cytokines and Their Cellular Receptors, Unit 6.12 Biological Responses to Chemokine Superfamily Members,” Current Protocols in Immunology, 1991, pp. 1-5.
Elworthy, Todd, R. et. al.,N-Arylpiperazinyl-N'-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α1-Adrenoceptor Antagonists, J. Med. Chem, 40, 1997, pp. 2674-2687.
Liang, M., et al.,Identification and Characterization of a Potent, Selective, and Orally Active Agonist of the CC Chemokine Receptor-1, Journal of Biological Chemistry, vol. 275, No. 25, pp. 19000-19008, (Jun. 23, 2000).
Benson Gregg C.
Pfizer Inc.
Raymond Richard L.
Verni Christopher J.
LandOfFree
Sulfonic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3499027